6 days Ago By ABMN Staff
Franklin Resources Inc. decreased its holdings in Catalyst Pharmaceuticals, Inc. ( NASDAQ:CPRX – Free Report ) by 1.
2% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 58,483 shares of the biopharmaceutical company’s stock after selling 681 shares during the period. Franklin Resources Inc.
’s holdings in Catalyst Pharmaceuticals were worth $1,221,000 at the end of the most recent quarter. Other hedge funds also recently made changes to their positions in the company. Steward Partners Investment Advisory LLC bought a new stake in Catalyst Pharmaceuticals in the 4th quarter valued at $27,000.
Farther Finance Advisors LLC raised its position in shares of Catalyst Pharmaceuticals by 125.1% in the fourth quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company’s stock valued at $56,000 after purchasing an additional 1,495 shares during the period.
Wilmington Savings Fund Society FSB acquired a new stake in shares of Catalyst Pharmaceuticals during the 4th quarter worth about $65,000. KBC Group NV lifted its stake in shares of Catalyst Pharmaceuticals by 48.8% during the 4th quarter.
KBC Group NV now owns 4,699 shares of the biopharmaceutical company’s stock worth $98,000 after buying an additional 1,542 shares during the last quarter. Finally, Thurston Springer Miller Herd & Titak Inc. bought a new stake in shares of Catalyst Pharmaceuticals during the 4th quarter worth about $134,000.
79.22% of the stock is owned by institutional investors and hedge funds. Insider Activity In related news, insider Gary Ingenito sold 44,904 shares of the firm’s stock in a transaction dated Wednesday, March 5th.
The stock was sold at an average price of $22.09, for a total value of $991,929.36.
Following the sale, the insider now directly owns 68,873 shares of the company’s stock, valued at $1,521,404.57. This trade represents a 39.
47 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link . Also, insider Brian Elsbernd sold 62,975 shares of the business’s stock in a transaction dated Monday, March 3rd.
The stock was sold at an average price of $22.98, for a total value of $1,447,165.50.
Following the transaction, the insider now directly owns 188,564 shares of the company’s stock, valued at approximately $4,333,200.72. The trade was a 25.
04 % decrease in their position. The disclosure for this sale can be found here . Corporate insiders own 11.
00% of the company’s stock. Catalyst Pharmaceuticals Stock Performance Analyst Upgrades and Downgrades A number of equities research analysts have recently issued reports on the company. Baird R W upgraded Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Monday, February 3rd.
HC Wainwright reaffirmed a “buy” rating and issued a $35.00 price objective on shares of Catalyst Pharmaceuticals in a report on Friday, February 28th. Stephens reiterated an “overweight” rating and set a $33.
00 price objective on shares of Catalyst Pharmaceuticals in a research report on Thursday, February 27th. Robert W. Baird boosted their target price on shares of Catalyst Pharmaceuticals from $28.
00 to $32.00 and gave the company an “outperform” rating in a research report on Monday, March 3rd. Finally, StockNews.
com raised shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 28th. Seven research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.
com, Catalyst Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $32.29. Get Our Latest Stock Analysis on CPRX Catalyst Pharmaceuticals Company Profile ( Free Report ) Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States.
It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. Further Reading Want to see what other hedge funds are holding CPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalyst Pharmaceuticals, Inc.
( NASDAQ:CPRX – Free Report ). Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter .
.
